Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Oric Pharmaceuticals (ORIC) Accumulated Depreciation & Amortization (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Accumulated Depreciation & Amortization readings, the most recent being $7.9 million for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 1.86% to $7.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Mar 2026, up 1.86% year-over-year, with the annual reading at $7.7 million for FY2025, 2.34% up from the prior year.
  • Accumulated Depreciation & Amortization hit $7.9 million in Q1 2026 for Oric Pharmaceuticals, up from $7.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $8.2 million in Q3 2025 and bottomed at $5.2 million in Q1 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $6.8 million, with a median of $6.7 million recorded in 2024.
  • The largest annual shift saw Accumulated Depreciation & Amortization increased 16.62% in 2025 before it grew 1.86% in 2026.
  • Oric Pharmaceuticals' Accumulated Depreciation & Amortization stood at $5.8 million in 2022, then increased by 12.1% to $6.5 million in 2023, then increased by 15.12% to $7.5 million in 2024, then grew by 2.34% to $7.7 million in 2025, then increased by 3.53% to $7.9 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Accumulated Depreciation & Amortization are $7.9 million (Q1 2026), $7.7 million (Q4 2025), and $8.2 million (Q3 2025).